ABCA1 | ATP-binding cassette, sub-family A (ABC1), member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| ![](/images/69889/ihc_selected_60x60.jpg) | ![](/images/57283/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/69889/151524_B_8_1_rna_selected_60x60.jpg) | Expressed in all |
ABCC1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| ![](/images/2380/ihc_selected_60x60.jpg) | | ![](/images/2380/ihc_cell_selected_60x60.jpg) | ![](/images/2380/8487_B_7_5_rna_selected_60x60.jpg) | Expressed in all |
ABCC2 | ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/4860/14118_B_8_6_rna_selected_60x60.jpg) | Group enriched |
ABCC8 | ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| ![](/images/42318/ihc_selected_60x60.jpg) | ![](/images/42318/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/11451/26291_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
ADORA1 | Adenosine A1 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| ![](/images_static/rna_center.gif) | ![](/images/52157/823_C8_2_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
ADRB2 | Adrenoceptor beta 2, surface | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| ![](/images/3431/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/3431/11305_B_9_4_rna_selected_60x60.jpg) | Mixed |
AGTR1 | Angiotensin II receptor, type 1 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images/3596/ihc_cell_selected_60x60.jpg) | ![](/images/3596/11016_B_9_3_rna_selected_60x60.jpg) | Group enriched |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| ![](/images/32148/ihc_selected_60x60.jpg) | ![](/images/32148/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/32148/77451_B_9_1_rna_selected_60x60.jpg) | Mixed |
ANXA1 | Annexin A1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Transporters
| | | | ![](/images/11271/29845_B_1_8_rna_selected_60x60.jpg) | Expressed in all |
ATP1A1 | ATPase, Na+/K+ transporting, alpha 1 polypeptide | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| ![](/images/18702/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/18702/42623_B_8_6_rna_selected_60x60.jpg) | Expressed in all |
ATP2C1 | ATPase, Ca++ transporting, type 2C, member 1 | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Transporters
| | ![](/images/10207/if_selected_60x60.jpg) | ![](/images/10207/ihc_cell_selected_60x60.jpg) | ![](/images/35116/84725_B_9_5_rna_selected_60x60.jpg) | Expressed in all |
ATP4A | ATPase, H+/K+ exchanging, alpha polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/39154/83027_B_9_7_rna_selected_60x60.jpg) | Tissue enriched |
ATP6V1B2 | ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 | FDA approved drug targets Predicted intracellular proteins Transporters
| | | ![](/images_static/rna_center.gif) | ![](/images/8147/23792_B_9_4_rna_selected_60x60.jpg) | Expressed in all |
AVPR1B | Arginine vasopressin receptor 1B | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| ![](/images/17337/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/17337/111003_B_7_8_rna_selected_60x60.jpg) | Not detected |
AVPR2 | Arginine vasopressin receptor 2 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| ![](/images/46678/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/46678/108998_A_3_1_rna_selected_60x60.jpg) | Mixed |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images/64258/1331_H7_1_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/64258/144292_A_4_3_rna_selected_60x60.jpg) | Tissue enhanced |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/39796/84042_B_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
CACNA1H | Calcium channel, voltage-dependent, T type, alpha 1H subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| ![](/images/39125/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/39125/91318_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
CACNA2D1 | Calcium channel, voltage-dependent, alpha 2/delta subunit 1 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/8621/24302_B_8_1_rna_selected_60x60.jpg) | Mixed |
CACNA2D2 | Calcium channel, voltage-dependent, alpha 2/delta subunit 2 | FDA approved drug targets Predicted intracellular proteins Transporters
| ![](/images/34771/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/34771/141854_B_8_1_rna_selected_60x60.jpg) | Tissue enriched |
CACNB2 | Calcium channel, voltage-dependent, beta 2 subunit | Disease related genes FDA approved drug targets Predicted intracellular proteins Transporters
| ![](/images/35326/ihc_selected_60x60.jpg) | ![](/images/35326/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/35326/73365_B_9_1_rna_selected_60x60.jpg) | Mixed |
CACNB3 | Calcium channel, voltage-dependent, beta 3 subunit | FDA approved drug targets Predicted intracellular proteins Transporters
| ![](/images_static/rna_center.gif) | ![](/images/59515/1070_B12_2_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Mixed |
CACNB4 | Calcium channel, voltage-dependent, beta 4 subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Transporters
| ![](/images/15601/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/15601/38980_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
CAMLG | Calcium modulating ligand | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| ![](/images/52636/ihc_selected_60x60.jpg) | ![](/images/52636/if_selected_60x60.jpg) | ![](/images/52636/ihc_cell_selected_60x60.jpg) | ![](/images/52636/121720_A_3_4_rna_selected_60x60.jpg) | Expressed in all |
CASR | Calcium-sensing receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images/39686/158078_A_4_8_selected_60x60.jpg) | ![](/images/50335/143981_B_7_7_rna_selected_60x60.jpg) | Tissue enhanced |
CFTR | Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/21939/147487_B_6_5_rna_selected_60x60.jpg) | Tissue enhanced |
CHRNA4 | Cholinergic receptor, nicotinic, alpha 4 (neuronal) | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| ![](/images/34064/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/34064/70739_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
CHRNA7 | Cholinergic receptor, nicotinic, alpha 7 (neuronal) | FDA approved drug targets Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/29422/64608_B_8_5_rna_selected_60x60.jpg) | Mixed |
CNR1 | Cannabinoid receptor 1 (brain) | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Transporters
| ![](/images/5603/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/5603/15927_A_5_3_rna_selected_60x60.jpg) | Tissue enhanced |
CYSLTR1 | Cysteinyl leukotriene receptor 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| ![](/images/10546/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/10546/26409_B_7_7_rna_selected_60x60.jpg) | Mixed |
FXYD2 | FXYD domain containing ion transport regulator 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/68838/154055_A_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
GABBR2 | Gamma-aminobutyric acid (GABA) B receptor, 2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/13820/142579_B_8_2_rna_selected_60x60.jpg) | Tissue enriched |
GABRB2 | Gamma-aminobutyric acid (GABA) A receptor, beta 2 | FDA approved drug targets Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/67632/156995_A_6_2_rna_selected_60x60.jpg) | Tissue enriched |
GLRA1 | Glycine receptor, alpha 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| ![](/images/16502/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/16502/38725_B_7_8_rna_selected_60x60.jpg) | Not detected |
GLRA2 | Glycine receptor, alpha 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/70422/153647_B_8_8_rna_selected_60x60.jpg) | Group enriched |
GLRB | Glycine receptor, beta | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| ![](/images/52363/155473_B_8_6_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/52363/155470_A_6_1_rna_selected_60x60.jpg) | Tissue enhanced |
GRIN1 | Glutamate receptor, ionotropic, N-methyl D-aspartate 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins Transporters
| ![](/images/6831/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/6831/17836_B_9_1_rna_selected_60x60.jpg) | Tissue enriched |
HMGCR | 3-hydroxy-3-methylglutaryl-CoA reductase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images/8338/ihc_cell_selected_60x60.jpg) | ![](/images/8338/23048_A_6_1_rna_selected_60x60.jpg) | Expressed in all |
HTR2B | 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| ![](/images/12867/155361_A_9_4_selected_60x60.jpg) | ![](/images/63658/1361_B8_2_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/12867/155357_B_9_6_rna_selected_60x60.jpg) | Tissue enhanced |
KCNA2 | Potassium voltage-gated channel, shaker-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| ![](/images/1976/5304_B_7_7_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/1976/5303_B_8_7_rna_selected_60x60.jpg) | Group enriched |
KCNA3 | Potassium voltage-gated channel, shaker-related subfamily, member 3 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| ![](/images/16625/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/16625/39154_A_6_6_rna_selected_60x60.jpg) | Mixed |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/21516/109609_B_7_2_rna_selected_60x60.jpg) | Group enriched |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images/42434/134744_A_1_8_selected_60x60.jpg) | ![](/images/42434/134323_B_1_7_rna_selected_60x60.jpg) | Tissue enhanced |
KCNC3 | Potassium voltage-gated channel, Shaw-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| ![](/images/18041/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/18041/40716_A_3_8_rna_selected_60x60.jpg) | Mixed |
KCND2 | Potassium voltage-gated channel, Shal-related subfamily, member 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| ![](/images/29068/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/29068/64679_B_9_2_rna_selected_60x60.jpg) | Tissue enhanced |
KCND3 | Potassium voltage-gated channel, Shal-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| ![](/images/29452/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/29452/63952_B_2_5_rna_selected_60x60.jpg) | Mixed |
KCNH2 | Potassium voltage-gated channel, subfamily H (eag-related), member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| ![](/images/40783/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/40783/91893_B_7_7_rna_selected_60x60.jpg) | Tissue enhanced |
KCNJ1 | Potassium inwardly-rectifying channel, subfamily J, member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images/26962/ihc_cell_selected_60x60.jpg) | ![](/images/26962/65936_A_1_1_rna_selected_60x60.jpg) | Tissue enriched |
KCNJ8 | Potassium inwardly-rectifying channel, subfamily J, member 8 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| ![](/images/31066/ihc_selected_60x60.jpg) | ![](/images/31066/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/31066/63191_B_8_1_rna_selected_60x60.jpg) | Mixed |
KCNK3 | Potassium channel, subfamily K, member 3 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| ![](/images/26658/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/26658/55343_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |